greeksoup/ stock research

CVS Health (CVS) Q3 FY2025 earnings: revenue $102.9 billion, up 7.8% on the year

CVS Health Corp. (CVS) reported revenue of $102.9 billion for Q3 FY2025, the quarter ended 30 September 2025, up 7.8% on the same quarter a year earlier. Net income was -$4.0 billion, and diluted earnings per share $-3.13. The figures are the company's own, from the 10-Q it filed with the SEC on 29 October 2025.

Revenue
$102.9 billion
+7.8% on the year · +4.0% on the quarter
Q4 FY2023Q3 FY2025
Operating margin
-3.1%
0.9% a year earlier
Q4 FY2023Q3 FY2025
Net income
-$4.0 billion
Q4 FY2023Q3 FY2025
Diluted EPS
-$3.13
Q4 FY2023Q3 FY2025

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ3 FY2025Q2 FY2025Q3 FY2024On the quarterOn the yearLast 8 quarters
Revenue102,87198,91595,428+4.0%+7.8%
Cost of revenue57,04554,00552,948+5.6%+7.7%
Gross profit45,82644,91042,480+2.0%+7.9%
Gross margin44.5%45.4%44.5%
Operating income-3,2072,381832
Operating margin-3.1%2.4%0.9%
Interest expense784763752+2.8%+4.3%
Pre-tax income-3,4821,647105
Income tax50863434.0-19.9%+1,394.1%
Effective tax raten/a38.5%32.4%
Net income-3,9751,02187.0
Net margin-3.9%1.0%0.1%
Diluted EPS-$3.13$0.80$0.07
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ3 FY2025Q2 FY2025Q3 FY2024On the quarterOn the yearLast 8 quarters
Operating cash flow7961,897-745-58.0%
Capital expenditure698607670+15.0%+4.2%
Free cash flow98.01,290-1,415-92.4%
Free cash flow margin0.1%1.3%-1.5%
Cash from investing-2,087-1,024-3,347
Cash from financing-1,382806-1,588
Depreciation and amortisation1,1341,1711,161-3.2%-2.3%
Share-based compensation138136133+1.5%+3.8%
Buybacks0.00.0-1.0
Dividends paid846866837-2.3%+1.1%
Dividend per share$0.67$0.67$0.670.0%0.0%
Diluted shares, weighted1,269m1,270m1,259m-0.1%+0.8%
Shares outstanding at period end1,270m1,267m1,258m+0.2%+1.0%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ3 FY2025Q2 FY2025Q3 FY2024On the quarterOn the yearLast 8 quarters
Shareholders' equity72,92877,37974,944-5.8%-2.7%
Non-controlling interest182172162+5.8%+12.3%
Debt65,83666,49065,534-1.0%+0.5%
Operating lease liabilities14,00714,32815,258-2.2%-8.2%
Other liabilities102,37499,97496,529+2.4%+6.1%
Total liabilities and equity255,327258,343252,427-1.2%+1.1%
Goodwill85,47891,20391,272-6.3%-6.3%
Intangible assets25,98426,22427,817-0.9%-6.6%
Investments33,68732,24431,744+4.5%+6.1%
Cash and equivalents9,09811,7876,875-22.8%+32.3%
Receivables43,85740,65136,179+7.9%+21.2%
Inventory18,96217,44717,649+8.7%+7.4%
Other assets38,26138,78740,891-1.4%-6.4%
Total assets255,327258,343252,427-1.2%+1.1%

Questions

What was CVS Health's revenue in Q3 FY2025?

CVS Health (CVS) reported revenue of $102.9 billion for Q3 FY2025, the quarter ended 30 September 2025, up 7.8% on the same quarter a year earlier.

How much did CVS Health earn in Q3 FY2025?

Net loss for Q3 FY2025 was $4.0 billion, and the diluted loss per share $3.13.

When did CVS Health report Q3 FY2025 results?

CVS Health filed its 10-Q for the quarter ended 30 September 2025 with the SEC on 29 October 2025.

Quarterly results, the last 20 quarters

Q4 FY2021 *Q1 FY2022 †Q2 FY2022 †Q3 FY2022 †Q4 FY2022 * †Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue76,60476,82680,63681,15983,84685,27888,92189,76493,81388,43791,23495,42897,71094,58898,915102,871105,693100,426106,096108,399
Cost of revenue46,37845,50949,29050,36551,72851,45553,53654,68857,41948,07349,99852,94855,26851,05754,00557,04559,06055,44458,86261,185
Gross profit30,22631,31731,34630,79432,11833,82335,38535,07636,39440,36441,23642,48042,44243,53144,91045,82646,63344,98247,23447,214
Gross margin39%41%39%38%38%40%40%39%39%46%45%45%43%46%45%45%44%45%45%44%
Operating income2,2293,5454,669-3,9193,6593,4463,2343,6903,3732,2713,0458322,3683,3742,381-3,2072,1124,6804,7033,566
Operating margin3%5%6%-5%4%4%4%4%4%3%3%1%2%4%2%-3%2%5%4%3%
Interest expense608586583566552589686693690716732752758785763784787774757747
Pre-tax income1,5703,0014,129-4,4443,1502,8792,5703,0192,7051,5802,3371052,1262,6171,647-3,4821,3543,9383,9772,849
Tax rate17%22%26%n/a26%26%26%25%24%29%24%32%24%32%38%n/a-116%25%25%24%
Net income1,3062,3543,029-3,4062,3342,1361,9012,2612,0461,1131,77087.01,6441,7791,021-3,9752,9432,9432,9792,172
Net margin2%3%4%-4%3%3%2%3%2%1%2%0%2%2%1%-4%3%3%3%2%
Diluted EPS$0.97$1.77$2.29-$2.59$1.77$1.65$1.48$1.75$1.58$0.88$1.41$0.07$1.30$1.41$0.80-$3.13$2.30$2.30$2.31$1.68
Operating cash flow4,0053,5635,4439,123-1,9527,4385,9082,716-2,6364,9033,089-7451,8604,5561,8977963,3904,2496,3454,724
Capital expenditure5971,051408580688984591545911705638670768743607698784849691817
Free cash flow3,4082,5125,0358,543-2,6406,4545,3172,171-3,5474,1982,451-1,4151,0923,8131,29098.02,6063,4005,6543,907
Buybacks0.02,0000.00.01,5002,018-2.0-3.0-1.03,027-3.0-1.00.00.00.00.00.0n/an/an/a
Dividends paid660722740726719779795779779840858837838840866846845847878853
Shares outstanding1,322m1,306m1,312m1,315m1,300m1,279m1,282m1,287m1,288m1,252m1,256m1,258m1,260m1,262m1,267m1,270m1,271m1,273m1,278m1,280m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2025, filed 29 October 2025: the filing.